tiprankstipranks
Trending News
More News >
Fairchem Organics Ltd (IN:FAIRCHEMOR)
:FAIRCHEMOR
India Market
Advertisement

Fairchem Organics Ltd (FAIRCHEMOR) AI Stock Analysis

Compare
1 Followers

Top Page

IN:FAIRCHEMOR

Fairchem Organics Ltd

(FAIRCHEMOR)

Select Model
Select Model
Select Model
Neutral 47 (OpenAI - 4o)
Rating:47Neutral
Price Target:
₹686.00
▲(4.99% Upside)
Fairchem Organics Ltd faces significant challenges with financial performance and technical indicators both pointing to weaknesses. The high P/E ratio suggests overvaluation, adding to the risk profile. The lack of positive earnings call data or corporate events further underscores the need for caution.
Positive Factors
Strong Balance Sheet
A strong balance sheet with a high equity ratio indicates financial stability and the ability to withstand economic downturns, supporting long-term operations.
Diverse Revenue Streams
Diversified revenue streams across multiple industries reduce dependency on a single sector, enhancing resilience and growth potential.
Long-term Contracts
Long-term contracts provide predictable revenue, reducing volatility and supporting sustained financial performance.
Negative Factors
Declining Revenue
Declining revenue growth indicates potential challenges in market demand or competitive positioning, impacting future profitability.
Rising Leverage
Increased leverage can strain financial resources and limit strategic flexibility, posing risks to long-term financial health.
Cash Flow Challenges
Weak cash flow performance undermines the company's ability to fund operations and invest in growth, threatening long-term sustainability.

Fairchem Organics Ltd (FAIRCHEMOR) vs. iShares MSCI India ETF (INDA)

Fairchem Organics Ltd Business Overview & Revenue Model

Company DescriptionFairchem Organics Ltd (FAIRCHEMOR) is a leading player in the specialty chemicals sector, primarily focused on the production and supply of a diverse range of organic chemicals and intermediates. The company operates in various industries, including pharmaceuticals, agrochemicals, and personal care, providing innovative solutions to meet the unique needs of its clients. Fairchem's core product offerings include specialty chemicals, fine chemicals, and intermediates that are essential in the manufacturing processes of its customers.
How the Company Makes MoneyFairchem Organics Ltd generates revenue through the sale of its specialty chemicals and organic products to various sectors including pharmaceuticals, agrochemicals, and personal care industries. The company's revenue model is primarily based on direct sales to manufacturers and distributors, often through long-term contracts that ensure a steady stream of income. Key revenue streams include bulk orders from industrial clients, custom synthesis services, and collaborations with other chemical companies for joint development projects. Additionally, Fairchem may benefit from strategic partnerships with research institutions and other organizations, which can enhance its product offerings and expand its market reach, ultimately contributing to its earnings.

Fairchem Organics Ltd Financial Statement Overview

Summary
Fairchem Organics Ltd is experiencing financial stress with declining revenue, profitability, and cash flow metrics. The balance sheet is solid, but increasing leverage and reduced returns are concerning.
Income Statement
55
Neutral
Fairchem Organics Ltd has shown a significant decline in key profitability metrics over the last year, with the gross profit margin falling to 12.4% from previous highs. The net profit margin decreased to 4.1%, indicating challenges in maintaining profitability. Revenue growth is negative, with a 13.4% decrease from the previous year. The EBIT and EBITDA margins have also declined, reflecting operational inefficiencies.
Balance Sheet
70
Positive
The company maintains a solid balance sheet with a healthy equity ratio of 75.2%, suggesting strong financial stability. However, the debt-to-equity ratio has increased, signaling a rise in leverage. The return on equity (ROE) dropped to 7.3%, indicating reduced shareholder returns.
Cash Flow
40
Negative
Cash flow performance has weakened considerably, with a significant drop in free cash flow and a negative operating cash flow. The free cash flow to net income ratio is negative, highlighting cash flow challenges. The operating cash flow to net income ratio turned negative, underlining issues in cash generation relative to net income.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue5.04B5.38B6.21B6.47B6.42B3.96B
Gross Profit619.37M666.52M1.54B1.56B1.78B1.25B
EBITDA274.63M441.21M681.10M729.68M1.05B688.05M
Net Income92.96M219.74M405.00M435.01M679.06M424.85M
Balance Sheet
Total Assets0.004.02B3.34B3.42B3.24B2.59B
Cash, Cash Equivalents and Short-Term Investments82.00K12.86M84.00K838.00K83.00K460.00K
Total Debt0.00630.32M73.18M501.68M620.30M568.03M
Total Liabilities-3.02B997.98M443.77M831.48M919.26M898.68M
Stockholders Equity3.02B3.02B2.90B2.59B2.32B1.69B
Cash Flow
Free Cash Flow0.00-464.87M563.52M348.89M58.91M163.03M
Operating Cash Flow0.00-203.78M744.80M496.15M404.85M394.26M
Investing Cash Flow0.00-255.71M-176.25M-144.92M-341.84M-228.02M
Financing Cash Flow0.00459.49M-568.55M-351.24M-63.19M-166.29M

Fairchem Organics Ltd Technical Analysis

Technical Analysis Sentiment
Negative
Last Price653.40
Price Trends
50DMA
738.58
Negative
100DMA
801.10
Negative
200DMA
854.11
Negative
Market Momentum
MACD
-26.42
Positive
RSI
35.27
Neutral
STOCH
16.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:FAIRCHEMOR, the sentiment is Negative. The current price of 653.4 is below the 20-day moving average (MA) of 687.47, below the 50-day MA of 738.58, and below the 200-day MA of 854.11, indicating a bearish trend. The MACD of -26.42 indicates Positive momentum. The RSI at 35.27 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:FAIRCHEMOR.

Fairchem Organics Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
63
Neutral
₹9.66B14.540.41%13.01%32.44%
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
60
Neutral
₹11.22B12.581.16%0.69%-7.54%
60
Neutral
₹11.80B29.680.25%-4.07%-12.36%
49
Neutral
₹11.34B23.350.76%-2.41%178.19%
47
Neutral
₹8.41B138.911.14%-22.10%-85.56%
46
Neutral
₹8.53B165.2216.43%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:FAIRCHEMOR
Fairchem Organics Ltd
653.40
-169.06
-20.56%
IN:AMNPLST
Amines & Plasticizers Ltd.
197.00
-69.61
-26.11%
IN:INDOAMIN
Indo Amines Limited
123.30
-50.39
-29.01%
IN:JAYAGROGN
Jayant Agro-Organics Limited
214.65
-72.23
-25.18%
IN:MANALIPETC
Manali Petrochemicals Limited
65.14
3.44
5.58%
IN:VALIANTORG
Valiant Organics Limited
253.05
-83.60
-24.83%

Fairchem Organics Ltd Corporate Events

Fairchem Organics Releases Unaudited Financial Results for September 2025
Nov 10, 2025

Fairchem Organics Limited has announced the publication of its unaudited financial results for the quarter and six months ending September 30, 2025, in prominent newspapers. The financial results, approved by the Board of Directors, provide stakeholders with insights into the company’s financial performance during this period, potentially impacting investor confidence and market positioning.

Fairchem Organics Releases Q2 FY 2025-26 Earnings Presentation
Nov 10, 2025

Fairchem Organics Limited has released its earnings presentation for the second quarter and the first half of the fiscal year 2025-26. This announcement, made in compliance with SEBI regulations, provides stakeholders with insights into the company’s financial performance, potentially impacting its market positioning and investor relations.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 19, 2025